Dapagliflozin
Top HF news of 2019: A paradigm shift in pharmacotherapy

Healio and Cardiology Today present a list of the most-read articles related to HF and transplantation published in 2019. Readers were most interested in new data that show benefit of SGLT2 inhibition in patients with HF, even in the absence of diabetes; sacubitril/valsartan for HF with preserved ejection fraction, sex-specific prevention and more.
The Take Home: AHA Scientific Sessions
FDA grants priority review to dapagliflozin for HFrEF treatment
New insights on diabetes, CVD research from the TIMI Study Group
VIDEO: New trials expand treatment options for diabetes, CVD
LOS ANGELES — In this video exclusive, Robert P. Giugliano, MD, SM, FACC, FAHA, clinical cardiologist at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School, presents an overview of recent trials from the Thrombolysis in Myocardial Infarction (TIMI) Study Group that advance the understanding of new therapies for diabetes, cardiovascular disease and beyond.
Top news of November: AHA highlights, electrophysiology training ‘crisis’ and more

Healio and Cardiology Today have compiled a list of the most-viewed cardiology articles in November. This month, our readers were most interested in highlights from the American Heart Association Scientific Sessions including COLCOT and ISCHMIA, the impact of vitamin D and fish oil on HF hospitalization risk, a commentary on the decline of cardiology fellows pursuing electrophysiology training and more.
VIDEO: Cardiometabolic knowledge broadened at AHA
PHILADELPHIA — In this video exclusive, Robert H. Eckel, MD, professor emeritus of medicine in the division of endocrinology, metabolism and diabetes at the University Colorado, past president of the American Heart Association and president-elect of the American Diabetes Association, discusses several highlights from the AHA Scientific Sessions.
DAPA-HF: Dapagliflozin’s HF benefits consistent regardless of age, symptom severity

PHILADELPHIA — Treatment with the SGLT2 inhibitor dapagliflozin reduced risk for CV death and worsening HF across a broad spectrum of age, independent of symptomatic impairment at baseline, according to two new post-hoc analyses of the DAPA-HF trial presented at the American Heart Association Scientific Sessions.
Top news of October: Sleep duration implications, statin intolerance and more

Healio and Cardiology Today compiled a list of the most-viewed cardiology posts in September. This month, our readers were interested in recalls of losartan due to impurities, the DAPA-HF and DEFINE-HF studies showing benefit of dapagliflozin (Farxiga, AstraZeneca) in patients with HF regardless of diabetes status, the effect of a salt substitution regimen on hypertension and much more.